查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1807510

獸醫腫瘤市場（按動物類型、治療方式、癌症類型、給藥方法和最終用戶分類）—2025-2030 年全球預測

Veterinary Oncology Market by Animal Type, Treatment Mode, Cancer Type, Mode of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年獸醫腫瘤市場價值為 16.1 億美元，預計到 2025 年將成長至 18.4 億美元，複合年成長率為 14.01%，到 2030 年將達到 35.5 億美元。

主要市場統計數據
基準年2024年 16.1億美元
預計2025年 18.4億美元
預計2030年 35.5億美元
複合年成長率（%） 14.01%

全面介紹獸醫腫瘤學的突破性創新和市場動態，為未來的策略決策提供參考

獸醫腫瘤學領域已進入一個關鍵時代，其特點是技術快速進步、臨床模式不斷演變，以及癌症作為伴侶動物發病主要原因的認知度不斷提高。過去十年，分子診斷、微創治療和標靶治療的突破性進展，不僅改善了患者的治療效果，也提升了從業人員的診療能力。隨著寵物飼主越來越渴望採用類似人類腫瘤治療通訊協定的複雜治療方法，該行業面臨前所未有的對綜合治療途徑和精準主導的需求。

探索一個關鍵的轉折點，它將透過技術進步、個人化護理和共同研究模式徹底改變獸醫腫瘤學

在尖端診斷技術、精準醫療和合作研究框架的推動下，獸醫腫瘤學領域正在改變。基因組序列測定的最新進展使從業者能夠識別腫瘤特異性生物標記物，從而製定個人化治療方案。此外，包括單株抗體和癌症疫苗在內的免疫調節劑的出現，正在拓展傳統化療方案以外的治療方法。

評估 2025 年美國關稅對獸醫腫瘤供應鏈、研究成本和臨床可近性的深遠累積影響

2025年美國新關稅的實施，給整個獸醫腫瘤供應鏈帶來了巨大的成本壓力。醫藥化合物、實驗室試劑和專用醫療設備的進口關稅正在推高國內製造商和臨床服務供應商的採購成本。結果，生產利潤率正在縮水，必須重新調整定價策略，以吸收關稅相關的額外費用。對於依賴海外採購原料藥的治療方法來說，這種動態尤其嚴重，因為外匯波動和關稅使整體成本結構變得複雜。

按動物類型、治療方式、癌症類型、給藥方法和最終用戶分類的關鍵細分洞察

要理解獸醫腫瘤學的複雜格局，需要深入研究構成市場動態的多個細分領域。就動物類型而言，犬類癌症治療佔據服務需求的主導地位，這主要得益於淋巴瘤和乳癌的高發生率。同時，外來寵物（例如水生動物、鳥類、爬蟲類和兩棲動物）為針對性診斷和針對特定棲息地的治療方法提供了新的機會。

對美洲、歐洲、中東和非洲以及亞太地區的主要區域洞察凸顯了獸醫癌症趨勢的地理差異

區域動態對於了解獸醫腫瘤學在不同市場的發展至關重要。在美洲，強大的獸醫基礎設施、較高的寵物擁有率以及成熟的保險框架促進了先進治療方法和診斷方法的早期應用。美國憑藉其規範的生態系統引領產業發展，支持其快速商業化，而拉丁美洲市場則正逐步投資提升其腫瘤學能力，通常透過慈善活動和學術合作的方式。

主要企業概況和策略公司洞察：透過創新和夥伴關係塑造獸醫腫瘤學的競爭格局

關鍵參與者正在塑造獸醫腫瘤學領域的競爭格局，其特點是策略聯盟和有針對性的研發投資。全球製藥巨頭正在成立專注於腫瘤化合物的動物用藥品部門，而中型主要企業則透過其專有的生技藥品和疫苗平台實現差異化。診斷影像設備和軟體製造商正在與獸醫夥伴關係合作，將人工智慧主導的分析工具納入臨床工作流程。

為行業領導者提供可行的建議，以應對市場複雜性、最佳化資源配置並利用獸醫腫瘤學的新興機會

行業領導者必須採取積極主動的姿態，抓住獸醫腫瘤學領域的新機遇，並降低不斷變化的風險。優先投資免疫療法研究可以解鎖差異化的產品平臺，而擴展數位健康解決方案可以提高診斷的準確性和客戶參與。此外，與學術機構建立夥伴關係可以加速轉化研究資產的獲取，並提昇在臨床同行中的信譽。

穩健的調查方法，結合初步訪談、二次資料分析和嚴格的三角測量，確保獲得可靠的獸醫腫瘤學見解

本分析以嚴謹的調查方法為基礎，此方法將一手資料和二手資料的洞見進行三角檢驗。一手資料的收集包括對獸醫腫瘤學家、診斷實驗室主任和學術研究人員的深入訪談，以獲得關於臨床效果、營運挑戰和未滿足需求的第一手觀點。二手資料的研究則廣泛查閱同行評審期刊、臨床試驗註冊中心、專利申請和監管備案文件，以揭示技術進步和核准的軌跡。

定義獸醫腫瘤學現況和未來發展軌跡的關鍵發現、策略意義和產業觀點

在技​​術突破、不斷發展的治療模式以及戰略性產業聯盟的推動下，獸醫腫瘤學有望持續成長和創新。關鍵細分洞察揭示了不同動物類型和治療模式的細微機遇，而區域分析則強調了量身定做的市場進入和擴張策略的重要性。 2025年的關稅重組對近岸外包和供應鏈最佳化既帶來了挑戰，也帶來了獎勵，需要敏捷的領導和適應性策略。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 引入針對伴侶動物癌症的標靶免疫療法將推動市場成長
  • 擴大使用液態生物檢體診斷技術來早期發現犬貓腫瘤，從而降低治療成本
  • 生技公司與獸醫診所結成策略聯盟，加速寵物個人化癌症治療
  • 小動物腫瘤微創放射治療需求不斷成長，推動治療量增加
  • 擴大監管部門對新型獸用化療的核准，並增強了全部區域的治療組合
  • 透過遠端醫療平台的發展，提高犬腫瘤專家的遠距就診機會

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：2025年美國關稅的累積影響

8. 獸醫腫瘤市場（依動物類型）

  • 狗
  • 馬
  • 珍稀寵物
    • 水生物種
    • 鳥類
    • 爬蟲類和兩棲類
  • 貓

9. 獸醫腫瘤市場（依治療模式）

  • 化療
    • 烷化劑
    • 抗代謝藥
    • 細胞毒性藥物
    • 長春花生物鹼
  • 免疫療法
    • 癌症疫苗
    • 單株抗體
  • 放射線治療
    • 放射線治療
    • 體外放射治療
  • 外科手術
  • 標靶治療

第 10 章 獸醫腫瘤市場（依癌症類型）

  • 血管肉瘤
  • 淋巴瘤
  • 乳癌
  • 肥大細胞腫瘤
  • 骨癌

11. 依管理模式分類的獸醫腫瘤市場

  • 靜脈注射（IV）
  • 口服
  • 局部的

第 12 章獸醫腫瘤市場（依最終用戶）

  • 學術機構
  • 獸醫醫院和診所

13.美洲獸醫腫瘤市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲獸醫腫瘤市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區獸醫腫瘤市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • FPNV定位矩陣2024
  • 競爭分析
    • AB Science SA
    • Anivive Lifesciences
    • Ardent Animal Health, LLC
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale SA
    • Covetrus, Inc.
    • Elanco Animal Health Incorporated
    • ELIAS Animal Health
    • Fidocure
    • IDEXX Laboratories, Inc.
    • Karyopharm Therapeutics Inc.
    • Leroy Biotech SAS
    • Merck KGaA,
    • Morphogenesis, Inc.
    • Nippon Zenyaku Kogyo Co., Ltd.
    • PetCure Oncology LLC
    • PharmAust Limited
    • Rhizen Pharmaceuticals AG
    • Torigen Pharmaceuticals Inc.
    • Varian Medical Systems, Inc.
    • Vetco Pharmaceuticals Inc.
    • VetDC, Inc.
    • Virbac SA
    • VolitionRx Limited
    • Zoetis Inc.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-A339DAEF9FFF

The Veterinary Oncology Market was valued at USD 1.61 billion in 2024 and is projected to grow to USD 1.84 billion in 2025, with a CAGR of 14.01%, reaching USD 3.55 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.61 billion
Estimated Year [2025] USD 1.84 billion
Forecast Year [2030] USD 3.55 billion
CAGR (%) 14.01%

Unveiling a Comprehensive Introduction to the Breakthrough Innovations and Market Dynamics Transforming Veterinary Oncology and Informing Future Strategic Decisions

The veterinary oncology sector has entered a pivotal era defined by rapid technological progress, evolving clinical paradigms, and an increasing recognition of cancer as a dominant driver of morbidity in companion animals. Over the past decade, breakthroughs in molecular diagnostics, minimally invasive interventions, and targeted therapies have coalesced to advance both patient outcomes and practitioner capabilities. As pet owners grow more willing to pursue complex treatment regimens reminiscent of human oncology protocols, the industry is confronted with unprecedented demands for integrated care pathways and precision-driven therapeutics.

Moreover, the market dynamic is shaped by a convergence of factors including an aging pet population, heightened investment in translational research, and strategic partnerships between veterinary specialists and academic institutions. Consequently, stakeholders across pharmaceutical development, diagnostics, and clinical service delivery must navigate an increasingly sophisticated landscape that prioritizes efficacy, safety, and cost-effectiveness. In addition, regulatory bodies are progressively harmonizing standards related to drug approval and clinical trial design, setting the stage for accelerated product launches.

This executive summary distills the essential developments influencing veterinary oncology, from new tariff regimes impacting supply chains to granular segmentation insights that uncover niche growth pockets. By synthesizing prevalence trends, therapeutic innovations, and competitive dynamics, the following analysis equips decision-makers with a holistic perspective on current challenges and future trajectories. Readers will gain a clear understanding of transformative shifts, regional variances, company strategies, and actionable recommendations tailored to safeguard and amplify market positioning.

Exploring the Profound Transformative Shifts Revolutionizing Veterinary Oncology Through Technological Advancements, Personalized Care, and Collaborative Research Models

The veterinary oncology landscape is undergoing transformative shifts driven by the integration of cutting-edge diagnostics, precision therapeutics, and collaborative research frameworks. In recent years, advancements in genomic sequencing have enabled practitioners to identify tumor-specific biomarkers that inform individualized treatment plans. Furthermore, the emergence of immunomodulatory agents, including monoclonal antibodies and cancer vaccines, has expanded therapeutic arsenals beyond traditional chemotherapeutic regimens.

Simultaneously, radiation therapy techniques are benefiting from enhanced dosimetric planning and imaging modalities, allowing for targeted tumor ablation with reduced collateral tissue damage. Telemedicine platforms and digital pathology applications are streamlining case reviews and interdisciplinary consultations, thus accelerating decision-making and fostering knowledge exchange among oncology specialists. In addition, artificial intelligence and machine learning algorithms are being piloted to predict treatment responses, monitor disease progression, and optimize dosing strategies, representing a fundamental shift towards data-driven clinical protocols.

Moreover, the proliferation of specialized oncology centers within veterinary hospitals and the deepening engagement of academic institutions in clinical research are reinforcing a robust innovation pipeline. Partnerships between industry and academia are facilitating the translation of preclinical findings into veterinary-approved products, while cross-border collaborations extend access to novel therapies. As a result, veterinary oncology is transitioning from a nascent discipline to a mature ecosystem where multidisciplinary synergy drives continuous improvement in patient care and commercial viability.

Assessing the Far-Reaching Cumulative Impact of United States Tariffs on Veterinary Oncology Supply Chains, Research Costs, and Clinical Accessibility in 2025

The implementation of new United States tariffs in 2025 has introduced material cost pressures across the veterinary oncology supply chain. Import duties on pharmaceutical compounds, laboratory reagents, and specialized medical equipment have elevated procurement expenses for both domestic manufacturers and clinical service providers. Consequently, production margins are contracting, and pricing strategies must be recalibrated to absorb incremental tariff-related outlays. This dynamic is particularly acute for therapies reliant on active pharmaceutical ingredients sourced internationally, where exchange rate fluctuations and customs duties compound overall cost structures.

Furthermore, research and development initiatives are being influenced by the recalibrated economics of cross-border collaboration. Academic and biotech partners are reassessing the viability of joint programs that require frequent reagent transfers or clinical trial material shipments. In response, organizations are exploring localized manufacturing capabilities and nearshoring strategies to mitigate tariff exposure and streamline logistics. Regulatory pathways are also being reviewsed to accommodate in-country production of critical oncology drugs, thereby reducing dependency on imported supply and enhancing resilience against future trade policy shifts.

In addition to supply chain ramifications, practitioners are confronting the downstream impact on treatment affordability and accessibility. Pet owners facing elevated out-of-pocket expenses may delay or forgo recommended protocols, which could affect clinical outcomes and long-term revenue streams for service providers. As such, stakeholder dialogues are intensifying around alternative financing models, insurance partnerships, and tiered therapy frameworks to ensure that high-value oncology care remains within reach for a broad demographic of companion animal caretakers.

Revealing Key Segmentation Insights Across Animal Types, Treatment Modalities, Cancer Categories, Administration Modes, and End Users Driving Market Complexity

Understanding the complex mosaic of veterinary oncology requires a deep dive into multiple dimensions of segmentation that collectively shape market dynamics. When examining animal type, canine cancer care dominates service demand, driven by a high incidence of lymphoma and mammary carcinoma, while feline oncology is gaining traction through specialized protocols for mast cell tumors. Equine oncology remains a niche yet growing category, particularly for sarcoids and melanomas, whereas the exotic pets segment-comprising aquatic species, avian populations, and reptile and amphibian communities-presents emergent opportunities for targeted diagnostics and habitat-specific treatment regimens.

Treatment mode segmentation reveals a diversified therapeutic toolkit. Chemotherapy, with its subdivisions of alkylating agents, antimetabolites, cytotoxic compounds, and Vinca alkaloids, continues to be a mainstay. At the same time, immunotherapy platforms leveraging cancer vaccines and monoclonal antibodies are redefining response paradigms. Radiotherapy innovations, spanning brachytherapy to external beam radiotherapy, offer precision interventions that complement surgical excision and the expanding field of targeted molecular therapies.

Additional segmentation by cancer type highlights distinct prevalence and research priorities, with hemangiosarcoma and osteosarcoma presenting acute diagnostic and therapeutic challenges. Mode of administration, whether intravenous infusion, oral dosing, or topical application, influences patient compliance and quality-of-life considerations. Finally, end users split between academic institutions and veterinary hospitals and clinics underscore the interplay between clinical practice environments and investigational research settings, each driving unique adoption curves for novel oncology solutions.

Dissecting Critical Regional Insights Across the Americas, Europe Middle East Africa, and Asia Pacific to Illuminate Geographical Variations in Veterinary Oncology Trends

Regional dynamics are pivotal to understanding how veterinary oncology takes shape across diverse markets. In the Americas, robust veterinary infrastructure, high pet ownership rates, and mature insurance frameworks have facilitated early adoption of advanced therapies and diagnostic modalities. The United States leads with a tightly regulated ecosystem that supports rapid commercialization, while Latin American markets are progressively investing in upgraded oncology capabilities, often through philanthropic and academic collaborations.

Europe, the Middle East, and Africa exhibit a heterogeneous landscape. Western European nations benefit from established veterinary oncology centers and comprehensive regulatory harmonization across the European Medicines Agency, accelerating product approvals. In contrast, Middle Eastern markets are rapidly building clinical capacity through public-private partnerships, and several African regions are initiating foundational oncology programs, frequently supported by international aid and capacity-building initiatives.

Meanwhile, Asia-Pacific is experiencing accelerated expansion propelled by rising disposable incomes, changing pet ownership patterns, and government incentives for biotech research. Japan and Australia feature sophisticated veterinary networks with integrated research consortia, whereas China and Southeast Asia are witnessing burgeoning private sector investment in oncology diagnostics and telehealth platforms. Collectively, these regional nuances underscore the necessity of tailored market entry strategies and local stakeholder engagement to harness growth in veterinary oncology.

Profiling Leading Industry Players and Strategic Company Insights Shaping the Competitive Landscape of the Veterinary Oncology Sector Through Innovation and Partnerships

An array of leading companies is shaping the competitive contours of veterinary oncology, characterized by strategic alliances and targeted R&D investments. Global pharmaceutical powerhouses have launched specialized animal health divisions focusing on oncology compounds, while mid-tier specialist firms are differentiating through proprietary biologics and vaccine platforms. Makers of diagnostic imaging equipment and software are forging partnerships with veterinary hospitals to embed AI-driven analysis tools within clinical workflows.

In parallel, emerging biotech startups are carving out niches by advancing novel immunotherapies and gene editing approaches tailored to companion animals. These ventures often collaborate with academic research centers to expedite translational pipelines and secure early-stage validation. Additionally, contract research organizations are expanding service offerings to include veterinary-specific toxicology and pharmacokinetic studies, thus underpinning streamlined development cycles.

Mergers and acquisitions remain active levers for growth, as larger entities seek to augment their oncology portfolios with innovative solutions and geographic reach. Simultaneously, joint ventures between industry and university laboratories are cultivating incubators that accelerate proof-of-concept trials. As a result, the market landscape is increasingly defined by cross-sector synergies, where shared expertise and resource pooling drive faster adoption of next-generation oncology modalities.

Delivering Actionable Recommendations for Industry Leaders to Navigate Market Complexity, Optimize Resource Allocation, and Harness Emerging Opportunities in Veterinary Oncology

Industry leaders must adopt a proactive stance to seize emerging opportunities and mitigate evolving risks within veterinary oncology. Prioritizing investments in immunotherapeutic research can unlock differentiated product pipelines, while scaling digital health solutions enhances diagnostic accuracy and client engagement. Furthermore, establishing partnerships with academic institutions accelerates access to translational research assets and bolsters credibility among clinical peers.

Simultaneously, stakeholders should explore decentralized manufacturing strategies to alleviate tariff-induced cost pressures and fortify supply chain resilience. Cultivating in-region production capabilities and forging alliances with contract manufacturers can reduce lead times and stabilize pricing, thereby preserving stakeholder margins. In parallel, implementing tiered pricing models and alternative financing structures can sustain treatment uptake in the face of rising patient expenses.

To maintain competitive advantage, organizations must foster multidisciplinary teams that bridge veterinary oncology, data science, and regulatory affairs. Embedding continuous learning frameworks and cross-functional collaboration will expedite innovation cycles and ensure compliance with evolving approval pathways. Lastly, devising region-specific go-to-market approaches-rooted in local stakeholder insights and regulatory landscapes-will optimize product launches and reinforce market penetration initiatives.

Outlining a Robust Research Methodology Incorporating Primary Interviews, Secondary Data Analysis, and Rigorous Triangulation to Ensure Reliable Veterinary Oncology Insights

This analysis is anchored in a rigorous research methodology that triangulates insights from primary and secondary data sources. Primary data collection involved in-depth interviews with veterinary oncologists, diagnostic laboratory directors, and academic researchers to capture first-hand perspectives on clinical efficacy, operational challenges, and unmet needs. Secondary research encompassed extensive review of peer-reviewed journals, clinical trial registries, patent filings, and regulatory filings to map technological advancements and approval trajectories.

Quantitative data points were refined through cross-validation techniques, ensuring consistency between independent sources and resolving discrepancies via follow-up inquiries. A comprehensive segmentation framework was constructed to parse market dynamics across animal types, treatment modes, cancer types, administration methods, and end-user categories. Regional market characteristics were analyzed in the context of regulatory environments, healthcare infrastructure maturity, and sociocultural pet ownership trends.

Where applicable, statistical modeling and scenario analysis were applied to assess the impacts of tariff changes and supply chain disruptions. Limitations include evolving trade policies and potential regulatory shifts scheduled beyond the research cutoff of Q1 2025. Overall, this methodology ensures that conclusions and recommendations are grounded in robust empirical evidence and reflect the most current state of veterinary oncology.

Drawing a Conclusive Synthesis of Key Findings, Strategic Implications, and Industry Narratives That Define the Current State and Future Trajectory of Veterinary Oncology

In summary, veterinary oncology is poised for sustained growth and innovation, fueled by technological breakthroughs, evolving treatment paradigms, and strategic industry collaborations. Key segmentation insights reveal nuanced opportunities across animal types and therapeutic modalities, while regional analyses underscore the importance of tailored approaches to market entry and expansion. The 2025 tariff realignment presents both challenges and incentives for nearshoring and supply chain optimization, demanding agile leadership and adaptive strategies.

Competitive dynamics are being reshaped by targeted R&D investments from biotechnology startups, strategic alliances between industry and academia, and consolidation moves among established animal health divisions. As decision-makers prioritize immunotherapy, precision diagnostics, and digital health integration, they should remain vigilant to regulatory developments and cost pressures that influence treatment accessibility.

By leveraging the actionable recommendations outlined herein-ranging from decentralized manufacturing to multidisciplinary team structures-industry stakeholders can navigate complexity and secure long-term value creation. This comprehensive synthesis of current trends and future trajectories equips enterprises to drive innovation, enhance patient outcomes, and achieve sustainable competitive advantage in the veterinary oncology landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Adoption of targeted immunotherapy treatments for companion animal cancers driving market growth
  • 5.2. Increasing use of liquid biopsy diagnostics for early detection of canine and feline tumors reducing treatment costs
  • 5.3. Strategic partnerships between biotech firms and veterinary clinics to accelerate personalized cancer therapies in pets
  • 5.4. Rising demand for minimally invasive radiation therapy for small animal oncology boosting procedural volumes
  • 5.5. Expanding regulatory approvals for novel veterinary chemotherapeutics enhancing treatment portfolios across regions
  • 5.6. Growth of telemedicine platforms for remote oncology consultations improving access to canine cancer specialists

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Veterinary Oncology Market, by Animal Type

  • 8.1. Introduction
  • 8.2. Canine
  • 8.3. Equine
  • 8.4. Exotic Pets
    • 8.4.1. Aquatic Pets
    • 8.4.2. Birds
    • 8.4.3. Reptiles & Amphibians
  • 8.5. Feline

9. Veterinary Oncology Market, by Treatment Mode

  • 9.1. Introduction
  • 9.2. Chemotherapy
    • 9.2.1. Alkylating Agents
    • 9.2.2. Antimetabolites
    • 9.2.3. Cytotoxic Agents
    • 9.2.4. Vinca Alkaloids
  • 9.3. Immunotherapy
    • 9.3.1. Cancer Vaccines
    • 9.3.2. Monoclonal Antibodies
  • 9.4. Radiotherapy
    • 9.4.1. Brachytherapy
    • 9.4.2. External Beam Radiotherapy
  • 9.5. Surgery
  • 9.6. Targeted Therapy

10. Veterinary Oncology Market, by Cancer Type

  • 10.1. Introduction
  • 10.2. Hemangiosarcoma
  • 10.3. Lymphoma
  • 10.4. Mammary Carcinoma
  • 10.5. Mast Cell Tumors
  • 10.6. Osteosarcoma

11. Veterinary Oncology Market, by Mode of Administration

  • 11.1. Introduction
  • 11.2. Intravenous (IV)
  • 11.3. Oral
  • 11.4. Topical

12. Veterinary Oncology Market, by End User

  • 12.1. Introduction
  • 12.2. Academic Institutions
  • 12.3. Veterinary Hospitals & Clinics

13. Americas Veterinary Oncology Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Veterinary Oncology Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Veterinary Oncology Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AB Science SA
    • 16.3.2. Anivive Lifesciences
    • 16.3.3. Ardent Animal Health, LLC
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. Ceva Sante Animale S.A.
    • 16.3.6. Covetrus, Inc.
    • 16.3.7. Elanco Animal Health Incorporated
    • 16.3.8. ELIAS Animal Health
    • 16.3.9. Fidocure
    • 16.3.10. IDEXX Laboratories, Inc.
    • 16.3.11. Karyopharm Therapeutics Inc.
    • 16.3.12. Leroy Biotech S.A.S.
    • 16.3.13. Merck KGaA,
    • 16.3.14. Morphogenesis, Inc.
    • 16.3.15. Nippon Zenyaku Kogyo Co., Ltd.
    • 16.3.16. PetCure Oncology LLC
    • 16.3.17. PharmAust Limited
    • 16.3.18. Rhizen Pharmaceuticals AG
    • 16.3.19. Torigen Pharmaceuticals Inc.
    • 16.3.20. Varian Medical Systems, Inc.
    • 16.3.21. Vetco Pharmaceuticals Inc.
    • 16.3.22. VetDC, Inc.
    • 16.3.23. Virbac SA
    • 16.3.24. VolitionRx Limited
    • 16.3.25. Zoetis Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. VETERINARY ONCOLOGY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. VETERINARY ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. VETERINARY ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. VETERINARY ONCOLOGY MARKET: RESEARCHAI
  • FIGURE 26. VETERINARY ONCOLOGY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. VETERINARY ONCOLOGY MARKET: RESEARCHCONTACTS
  • FIGURE 28. VETERINARY ONCOLOGY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. VETERINARY ONCOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EQUINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY AQUATIC PETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY AQUATIC PETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BIRDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BIRDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REPTILES & AMPHIBIANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REPTILES & AMPHIBIANS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY FELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY FELINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VINCA ALKALOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VINCA ALKALOIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY HEMANGIOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY HEMANGIOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAMMARY CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAMMARY CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAST CELL TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAST CELL TUMORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 148. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 149. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 150. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 166. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 167. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 168. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 169. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 181. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 184. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 185. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 186. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 187. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 188. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 189. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 240. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 241. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 242. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 243. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 245. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 247. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 249. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 258. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 259. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 260. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 261. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 263. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 265. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 267. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 271. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. FRANCE VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 273. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 277. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 279. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 281. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 283. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 285. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 289. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 293. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 294. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 295. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 297. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 299. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 301. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 303. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 307. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 309. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 312. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 313. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 314. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 315. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 317. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 319. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 321. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 325. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. SPAIN VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 329. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2025-2030 (USD MILLION)
  • TABLE 331. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 333. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 335. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 337. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED ARAB EMIRATES VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 339. UNITED ARAB EMIRATES